IPA-3

Catalog No.S7093

For research use only.

IPA-3 is a selective non-ATP competitive Pak1 inhibitor with IC50 of 2.5 μM in a cell-free assay, no inhibition to group II PAKs (PAKs 4-6).

IPA-3 Chemical Structure

CAS No. 42521-82-4

Selleck's IPA-3 has been cited by 39 publications

Purity & Quality Control

Choose Selective PAK Inhibitors

Biological Activity

Description IPA-3 is a selective non-ATP competitive Pak1 inhibitor with IC50 of 2.5 μM in a cell-free assay, no inhibition to group II PAKs (PAKs 4-6).
Features IPA-3 binds covalently to the Pak1 regulatory domain and prevents binding to the upstream activator Cdc42.
Targets
PAK1 [1]
(Cell-free assay)
2.5 μM
In vitro

IPA-3 is a non ATP-competitive, allosteric inhibitor of p21-activated kinase 1 (Pak1). PIR3.5 is the control compound of IPA-3. IPA-3 prevents Cdc42-stimulated Pak1 autophosphorylation on Thr423. IPA-3 also prevents sphingosine-dependent Pak1 autophosphorylation. IPA-3 does not target exposed cysteine residues on Pak1. The disulfide bond of IPA-3 is critical for inhibition of Pak1 and in vitro reduction by the reducing agent dithiothreitol (DTT) abolishes Pak1 inhibition by IPA-3. IPA-3 inhibits activation of Pak1 by diverse activators, but does not inhibit preactivated Pak1. IPA-3 inhibits PDGF-stimulated Pak activation in mouse embryonic fibroblasts. [1] IPA-3 inhibits Pak1 activation in part by binding covalently to the regulatory domain of Pak1. IPA-3 binds Pak1 covalently in a time- and temperature-dependent manner. IPA-3 prevents binding of the Pak1 activator Cdc42. IPA-3 binds directly to the Pak1 autoregulatory domain. IPA-3 reversibly inhibits PMA-induced membrane ruffling in cells. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human NALM-6 cell MonIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGm3N4JKdmirYnn0bY9vKG:oIHj1cYFvKE6DTF2tOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTd4OUSg{txO M2eyS3NCVkeHUh?=
human SW1710 cell MmrpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHe3S|NKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOTd6M{Og{txO MkjFV2FPT0WU
human YT cell MmTKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYrUOW9NUW6qaXLpeIlwdiCxZjDoeY1idiC\VDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuN|kxOzZizszN MXHTRW5ITVJ?
human BL-70 cell NUW0R4pbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGewT5dKdmirYnn0bY9vKG:oIHj1cYFvKEKOLUewJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4xOzd7NjFOwG0> NET6fHpUSU6JRWK=
human SIG-M5 cell M1r5[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3fKbGlvcGmkaYTpc44hd2ZiaIXtZY4hW0mJLV21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4yODJzOTFOwG0> MVrTRW5ITVJ?
human MCF7 cell M2rPNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkPZTY5pcWKrdHnvckBw\iCqdX3hckBOS0Z5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6xPFA4KM7:TR?= MlHmV2FPT0WU
human GB-1 cell NEjNVW1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnjPTY5pcWKrdHnvckBw\iCqdX3hckBISi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj62N|Q6PCEQvF2= NVi0WZAzW0GQR1XS
human KU812 cell NGHNcGJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGtWQDF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj63OVk2KM7:TR?= MnvtV2FPT0WU
human QIMR-WIL cell NVfFcXdPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVe3b4JSUW6qaXLpeIlwdiCxZjDoeY1idiCTSV3SMXdKVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwOUC4PVEh|ryP MXvTRW5ITVJ?
human BL-41 cell MlHQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGJNNTRzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz6wPVg1PCEQvF2= M330NXNCVkeHUh?=
human CMK cell NYrR[5RYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH3PZ4hKdmirYnn0bY9vKG:oIHj1cYFvKEOPSzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNVQ2QTlizszN MlHPV2FPT0WU
human U-698-M cell NVHiUJViT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYLifmVWUW6qaXLpeIlwdiCxZjDoeY1idiCXLU[5PE1OKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5{M{i1OkDPxE1? M{\rfXNCVkeHUh?=
human Daoy cell NX3YXpAzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3jDWWlvcGmkaYTpc44hd2ZiaIXtZY4hTGGxeTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNlQ3PjJizszN NFS4WVFUSU6JRWK=
human 786-0 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWTJcohq[mm2aX;uJI9nKGi3bXHuJFc5Pi1yIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz6zNVgxPSEQvF2= MWLTRW5ITVJ?
human REH cell M4H5Xmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1jZRmlvcGmkaYTpc44hd2ZiaIXtZY4hWkWKIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz6zOlY2PSEQvF2= M2DsWnNCVkeHUh?=
human MHH-PREB-1 cell NXjMOYd1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MY\Jcohq[mm2aX;uJI9nKGi3bXHuJG1JUC2SUlXCMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjR4Nki3JO69VQ>? NFvNVnlUSU6JRWK=
human KE-37 cell growth NUW4N3BpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M165U2lvcGmkaYTpc44hd2ZiaIXtZY4hU0VvM{egZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlUxOjNzIN88US=> NYj6fFlCW0GQR1XS
human CAL-51 cell M2r4fWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWHJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC13MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOVQ2OTlizszN MYPTRW5ITVJ?
human CA46 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXXJcohq[mm2aX;uJI9nKGi3bXHuJGNCPDZiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Lk[2NVgh|ryP M4S4b3NCVkeHUh?=
human HEL cell M{S1PGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3TURWlvcGmkaYTpc44hd2ZiaIXtZY4hUEWOIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz63Nlc3QCEQvF2= MYLTRW5ITVJ?
human NB6 cell MmThS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1\nXmlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz64N|c2OSEQvF2= MYfTRW5ITVJ?
human 8305C cell MlH6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmHvTY5pcWKrdHnvckBw\iCqdX3hckA5OzB3QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNVY4PThizszN MV;TRW5ITVJ?
human EW-13 cell NHHpTo5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mo\RTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNlAyPDhizszN MWnTRW5ITVJ?
human NB13 cell NYjpd|VJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlPuTY5pcWKrdHnvckBw\iCqdX3hckBPSjF|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6yNlU3KM7:TR?= MoH3V2FPT0WU
human EB2 cell Mo\oS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NILMfplKdmirYnn0bY9vKG:oIHj1cYFvKEWEMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuOFkyPDJizszN MWXTRW5ITVJ?
human HOS cell Mk\KS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGLNVlVKdmirYnn0bY9vKG:oIHj1cYFvKEiRUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5 M2\mSnNCVkeHUh?=
human HLE cell NHrsWXdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlTrTY5pcWKrdHnvckBw\iCqdX3hckBJVEViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkWyNVQ6KM7:TR?= NX\DUJdrW0GQR1XS
human ST486 cell NFHnVXNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXTJcohq[mm2aX;uJI9nKGi3bXHuJHNVPDh4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND64OlU1KM7:TR?= NE[zb4xUSU6JRWK=
human NCI-H2009 cell M3rRXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkiwTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKwNFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjB2M{W0JO69VQ>? MV;TRW5ITVJ?
human NH-12 cell MmXnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVXzPGZjUW6qaXLpeIlwdiCxZjDoeY1idiCQSD2xNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOTF5NjFOwG0> NWfTZpJSW0GQR1XS
human BFTC-905 cell M4DtRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2fiTmlvcGmkaYTpc44hd2ZiaIXtZY4hSk[WQz25NFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjF2N{[4JO69VQ>? NXy3d|Z[W0GQR1XS
human RKO cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVLJcohq[mm2aX;uJI9nKGi3bXHuJHJMVyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwMki0O|Eh|ryP M3zKTnNCVkeHUh?=
human PF-382 NGfObnlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGXr[WRKdmirYnn0bY9vKG:oIHj1cYFvKFCILUO4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOzV{Mk[g{txO NYDHToRMW0GQR1XS
human SR cell NF7QTIdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnS0TY5pcWKrdHnvckBw\iCqdX3hckBUWiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwM{eyOVYh|ryP MV7TRW5ITVJ?
human WSU-NHL cell Ml:4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M33CPGlvcGmkaYTpc44hd2ZiaIXtZY4hX1OXLV7IUEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPTJyNkeg{txO MYXTRW5ITVJ?
human CAL-12T cell M{jmdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlywTY5pcWKrdHnvckBw\iCqdX3hckBESUxvMULUJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU43PDF2IN88US=> MmDTV2FPT0WU
human Daudi cell NWrvVJE5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlnSTY5pcWKrdHnvckBw\iCqdX3hckBF[XWmaTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOlg1PzdizszN NVXrfWJMW0GQR1XS
human MC-CAR cell MnfmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVnYR4J7UW6qaXLpeIlwdiCxZjDoeY1idiCPQz3DRXIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjdyNkS0JO69VQ>? NIS3[VZUSU6JRWK=
human RPMI-8402 cell NIHWUYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{jDdGlvcGmkaYTpc44hd2ZiaIXtZY4hWlCPST24OFAzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS55Nki3OkDPxE1? NEDyRY9USU6JRWK=
human CCRF-CEM cell NIi0UZZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnmwTY5pcWKrdHnvckBw\iCqdX3hckBES1KILVPFUUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTd4Nkeg{txO MVPTRW5ITVJ?
human CHP-126 cell NX;pPJl3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYTJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1zMk[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22Mlc1OjZ6IN88US=> NIOwVZNUSU6JRWK=
human NB69 cell MkPlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M37pfGlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uO|Y{PTJizszN MoP0V2FPT0WU
human KS-1 cell NIqxOlZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXzmb2xrUW6qaXLpeIlwdiCxZjDoeY1idiCNUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok45QDV2OTFOwG0> MmO1V2FPT0WU
human J82 cell NXXPeFZ4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGjwR49KdmirYnn0bY9vKG:oIHj1cYFvKEp6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuNFQ6PjVizszN MonaV2FPT0WU
human SW872 cell NYHPWpNIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MofzTY5pcWKrdHnvckBw\iCqdX3hckBUXzh5MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuPFM2PThizszN Ml7kV2FPT0WU
human HC-1 cell NF\LOGpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFnBdphKdmirYnn0bY9vKG:oIHj1cYFvKEiFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlA3QDB3IN88US=> MVfTRW5ITVJ?
human DU-145 cell NEfwTndIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX75R3NQUW6qaXLpeIlwdiCxZjDoeY1idiCGVT2xOFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF05NjJzNE[0JO69VQ>? NH64S5FUSU6JRWK=
human HL-60 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVzJcohq[mm2aX;uJI9nKGi3bXHuJGhNNTZyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OD64OFYxPSEQvF2= MlPKV2FPT0WU
human MV-4-11 cell NWjINGpWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYDJcohq[mm2aX;uJI9nKGi3bXHuJG1XNTRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25MlE3PDlizszN NXiwNIdsW0GQR1XS
human SK-N-DZ cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3PxVmlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTj3EXkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvOjB2MkOg{txO Mly0V2FPT0WU
human HT-1197 cell NVPaOmdIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmnhTY5pcWKrdHnvckBw\iCqdX3hckBJXC1zMUm3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVAvOzB5MzFOwG0> MlrNV2FPT0WU
human NOS-1 cell Mn3hS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn3BTY5pcWKrdHnvckBw\iCqdX3hckBPV1NvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGxMlcyPTJizszN MYTTRW5ITVJ?
human HT-1080 cell M1u4VWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVvG[XVHUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xNFgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OThwNkK4N{DPxE1? NX7CcI9EW0GQR1XS
human SK-LU-1 cell NWrSVmhiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWnJcohq[mm2aX;uJI9nKGi3bXHuJHNMNUyXLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xPE45PzNzIN88US=> NGX2OVVUSU6JRWK=
human SW48 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXLJcohq[mm2aX;uJI9nKGi3bXHuJHNYPDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{MT64PFk4KM7:TR?= NVjsemVHW0GQR1XS
human A2780 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWfJcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkiuN|cyKM7:TR?= Ml7rV2FPT0WU
Assay
Methods Test Index PMID
Growth inhibition assay Cell viability 30971268
Western blot p-PAK1 / PAK1 / p-PAK2 / PAK2 / p-Raf1 / Raf1 / p-MEK1 / MEK1 / p-ERK / ERK 30971268
Immunofluorescence BiP ; NF-κB ; Paxillin 24844382 23894351

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 70 mg/mL
(199.74 mM)
Ethanol 7 mg/mL
(19.97 mM)
Water Insoluble

Chemical Information

Molecular Weight 350.45
Formula

C20H14O2S2

CAS No. 42521-82-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=CC=C2C(=C1)C=CC(=C2SSC3=C(C=CC4=CC=CC=C43)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
If this product is cell membrane permeable and would it be suitable for PAK1 inhibition on a pancreatic beta cell line?

Answer:
Based on the reference, I think IPA-3 is able to penetrate the cell membrane, it's likely to inhibit PAK1 on a pancreatic beta cell line although there is no reference confirming it: Figure 3: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963893/; http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353635/

Tags: buy IPA-3 | IPA-3 supplier | purchase IPA-3 | IPA-3 cost | IPA-3 manufacturer | order IPA-3 | IPA-3 distributor